Sangamo Competitors
| SGMO Stock | USD 0.40 0.05 14.29% |
Sangamo Therapeutics vs Lipocine Correlation
Very good diversification
The correlation between Sangamo Therapeutics and LPCN is -0.42 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sangamo Therapeutics and LPCN in the same portfolio, assuming nothing else is changed.
Moving against Sangamo Stock
| 0.37 | ENGN | enGene Holdings Common | PairCorr |
| 0.36 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.35 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.32 | DSGN | Design Therapeutics | PairCorr |
Sangamo Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sangamo Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sangamo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sangamo Therapeutics does not affect the price movement of the other competitor.
| 0.85 | -0.26 | 0.74 | -0.87 | GOVX | ||
| 0.85 | -0.1 | 0.64 | -0.73 | BLRX | ||
| -0.26 | -0.1 | 0.2 | 0.4 | THAR | ||
| 0.74 | 0.64 | 0.2 | -0.57 | AIMD | ||
| -0.87 | -0.73 | 0.4 | -0.57 | LPCN | ||
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sangamo Stock performing well and Sangamo Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sangamo Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 5.33 | (2.41) | 0.00 | (0.83) | 0.00 | 9.38 | 42.89 | |||
| BLRX | 2.59 | (0.27) | 0.00 | (0.19) | 0.00 | 5.20 | 13.04 | |||
| THAR | 5.48 | 0.50 | 0.08 | 0.40 | 5.92 | 11.55 | 40.06 | |||
| AIMD | 4.50 | (0.89) | 0.00 | (0.22) | 0.00 | 12.30 | 38.73 | |||
| LPCN | 5.03 | 2.00 | 0.39 | (14.40) | 3.32 | 15.95 | 33.09 |
Cross Equities Net Income Analysis
Compare Sangamo Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GOVX | 36.7 M | (2.3 M) | (2.1 M) | (2.3 M) | (2.7 M) | (2.7 M) | (3.3 M) | (2.2 M) | (2.6 M) | (2.4 M) | (2.9 M) | (18.5 M) | (14 M) | (26 M) | (25 M) | (22.5 M) | (21.4 M) |
| BLRX | (32.1 M) | (13.2 M) | (20.4 M) | (17.6 M) | (10.2 M) | (14.4 M) | (15.8 M) | (24.4 M) | (23 M) | (25.4 M) | (30 M) | (27.1 M) | (25 M) | (60.6 M) | (9.2 M) | (8.3 M) | (8.7 M) |
| THAR | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (2.4 M) | (2.2 M) | (8.5 M) | (9.3 M) | (12.2 M) | (11 M) | (10.4 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| LPCN | (5.2 K) | (5.2 K) | (76.7 K) | (10.6 M) | (20.4 M) | (18.2 M) | (19 M) | (21 M) | (11.7 M) | (13 M) | (21 M) | (634.4 K) | (10.8 M) | (16.4 M) | 8.4 K | 7.5 K | 7.9 K |
Sangamo Therapeutics and related stocks such as GeoVax Labs, BioLineRx, and Tharimmune Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sangamo Therapeutics financial statement analysis. It represents the amount of money remaining after all of Sangamo Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sangamo Therapeutics Competitive Analysis
The better you understand Sangamo Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sangamo Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sangamo Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sangamo Therapeutics Competition Performance Charts
Five steps to successful analysis of Sangamo Therapeutics Competition
Sangamo Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sangamo Therapeutics in relation to its competition. Sangamo Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sangamo Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sangamo Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sangamo Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sangamo Therapeutics position
In addition to having Sangamo Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sangamo Therapeutics Correlation with its peers. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Biotechnology sector continue expanding? Could Sangamo diversify its offerings? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sangamo Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.45) | Revenue Per Share | Quarterly Revenue Growth (0.99) | Return On Assets | Return On Equity |
Sangamo Therapeutics's market price often diverges from its book value, the accounting figure shown on Sangamo's balance sheet. Smart investors calculate Sangamo Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Sangamo Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.